Homefurnishing Retail

XenoPort Inc (NASDAQ: XNPT) shares moved up 67.16% to $10.66 at 10:12 am. The volume of XNPT shares traded was 4112% higher than normal. GlaxoSmithKline Plc (NYSE: GSK) and XNPT received approval from the US Food and Drug Administration (FDA) for the drug Horizant. Bed Bath & Beyond Inc (...

March same-store sales have been released for the retail sector and overall the results are positive, with the majority of reports exceeding the Street consensus. Factors stated by retailers as affecting March's numbers include this year's Easter timing three weeks later in 2011 than in 2010, the...

Masimo Corporation (NASDAQ: MASI) shares jumped 2.35% to create a new 52-week high of $34.43. MASI's trailing-twelve-month ROE is 28.25%. Rent-A-Center Inc (NASDAQ: RCII) shares gained 1.76% to touch a new 52-week high of $36.33. RCII is scheduled to post its Q1 results on April 25. Century...

Gilford Securities is out with its report today on Bed Bath & Beyond (NASDAQ: BBBY), reiterating Buy after strong SSS in 4Q10. In a note to clients, Gilford Securities writes, "An 8.5% same-store sales gain for 4Q/F10 came on top of an 11.5% gain a year ago, and compared with guidance for a...

Shares of Stage Stores Inc (NYSE: SSI) fell about 0.5% after the company reported 5.3% decline in its March sales at stores open at least one year. However, analysts were expecting same-store sales to drop 6.5%. SSI's total sales for the five weeks ended April 2 dropped 4.1% to $134 million....

Shares of Bed Bath & Beyond (NASDAQ: BBBY) have hit a 52-week high in early trading. At last check, the year-to-date performance of Bed Bath & Beyond has seen an 11% gain.

Sterne Agee is out with its report today on Bed Bath & Beyond (NASDAQ: BBBY), maintaining Neutral. In a note to clients, Sterne Agee writes, "While we continue to view BBBY as a strong and consistent operator with viable long-term growth prospects, we note that potential for operating margin...

Oppenheimer views Bed Bath & Beyond's (NASDAQ: BBBY) Q4 report Wed. evening as nothing short of stellar. Q4 EPS of $1.12 easily topped a Street figure of $0.97. A further acceleration in sales and a reversal in gross margin trends fueled EPS upside. Citi had been concerned that higher input...

Best 1) XenoPort (NASDAQ: XNPT): Posting a huge pre-market gain of 68.61% to $10.77. An FDA approval for its drug, along with partner GlaxoSmithKline (NYSE: GSK), has shares skyrocketing. 2) ZAGG (NASDAQ: ZAGG): Trading up 13% to $9.28. Investors are responding well to an agreement with Logitech...

Goldman Sachs has issued a report raising the Price Target on Bed Bath & Beyond (NASDAQ: BBBY) from $56 to $62 a share. According to the report, "We raise our 12-month price target to $62 from $56, on our estimate hikes, the expectation of some favorable re-rating based on strong results, and...

XenoPort Inc (NASDAQ: XNPT) added 70.85% to $10.90 in the pre-market session. GlaxoSmithKline Plc (NYSE: GSK) and XNPT received approval from the US Food and Drug Administration (FDA) for Horizant. ZAGG Incorporated (NASDAQ: ZAGG) moved up 11.66% to $9.10 in the pre-market session. ZAGG signed an...

According to Sterne Agee, Bed Bath & Beyond (NASDAQ: BBBY) posted another impressive beat, with Q4 EPS of $1.12 (vs. $0.86 LY), well above our estimate of $0.96 and FC of $0.97, both of which were above the high end of the $0.91-$0.95 guidance range. Sterne Agee reported that SSS gained a...

J.P. Morgan is raising its PT on shares of Bed Bath & Beyond, Inc. (NASDAQ: BBBY). “BBBY reported a very impressive end to its FY end (February) with 4Q earnings growth of 30% and same-store sales of 8.5% vs. 3.0%E,” J.P. Morgan writes. “Based on this momentum and the flowthrough effect on our...

Wedbush is out with its report today on Bed Bath & Beyond (NASDAQ: BBBY), raising its price target from $58 to $63. In a note to clients, Wedbush writes, "Raising our price target to $63 (from $58), which assumes BBBY should trade at 16x our revised 2011 EPS estimate of $3.48, plus nearly $8...

Haverty Furniture Companies Inc (NYSE: HVT) reported its Q1 sales at $154.2 million, versus the consensus of $152.4 million. HVT reported 0.6% decline in its Q1 same-store sales. HVT shares gained 0.37% to close at $13.50 yesterday. Read more from Benzinga's Company news.